Lycera Corp - Company & Market Research Reports

Lycera is a biopharmaceutical company that is developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer. The company offers novel oral medicines for diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease. Its lead product is LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease. Lycera was founded in 2006 and is headquartered in Ann Arbor, Michigan.

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth - Product Thumbnail Image

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth

  • Report
  • 101 Pages
From
Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

  • Report
  • 150 Pages
From
Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence - Product Thumbnail Image

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

  • Report
  • 171 Pages
From
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence - Product Thumbnail Image

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence

  • Report
  • 170 Pages
From
Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth - Product Thumbnail Image

Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

  • Report
  • 94 Pages
From
Ulcerative Colitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Review, H1 2018

  • Report
  • 482 Pages
From
Psoriasis - Pipeline Review, H1 2018 - Product Thumbnail Image

Psoriasis - Pipeline Review, H1 2018

  • Report
  • 709 Pages
From
Inflammatory Bowel Disease - Pipeline Review, H2 2015 - Product Thumbnail Image

Inflammatory Bowel Disease - Pipeline Review, H2 2015

  • Report
  • 1025 Pages
From
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016 - Product Thumbnail Image

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

  • Report
  • 294 Pages
From
Dermatology Therapeutics Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Dermatology Therapeutics Drug Development Pipeline Review, 2016

  • Report
  • 432 Pages
From
RORgamma Modulators 2016: A comparative Analysis of the Landscape of RORgamma Antagonists and Agonists - Product Thumbnail Image

RORgamma Modulators 2016: A comparative Analysis of the Landscape of RORgamma Antagonists and Agonists

  • Report
  • 88 Pages
From
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018 - Product Thumbnail Image

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2018

  • Report
  • 106 Pages
From
Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022

  • Report
  • 157 Pages
From
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018 - Product Thumbnail Image

H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) - Pipeline Review, H1 2018

  • Report
  • 44 Pages
From
Esophageal Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Esophageal Cancer - Pipeline Review, H1 2018

  • Report
  • 639 Pages
From
Gastric Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H1 2018

  • Report
  • 1283 Pages
From
Head And Neck Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Review, H1 2018

  • Report
  • 1639 Pages
From
Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • 749 Pages
From
Bladder Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Bladder Cancer - Pipeline Review, H1 2018

  • Report
  • 999 Pages
From
Bladder Cancer - Pipeline Review, H2 2017 - Product Thumbnail Image

Bladder Cancer - Pipeline Review, H2 2017

  • Report
  • 937 Pages
From
Loading Indicator
adroll